Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07136077 | A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy | PHASE2 | RECRUITING | 20 | — | — | Sep 18, 2025 | Apr 1, 2028 | Apr 6, 2026 | 1 | United States |
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
| Arm | Type | Description |
|---|---|---|
| Phase II: Treatment with Fruquintinib and Tislelizumab | EXPERIMENTAL | Treatment with Fruquintinib and Tislelizumab |
| Name | Type | Description |
|---|---|---|
| Tislelizumab | DRUG | Given by IV |
| Fruquintinib | DRUG | Give by PO |
Eligibility Criteria * Participants must have histologically or cytologically confirmed microsatellite stable (MSS) colorectal adenocarcinoma. * Participants must have completed curative intent treatments of stages II, III, or IV colorectal cancer that must include ≥ 3 months of oxaliplatin contain...